An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2018
Price : $35 *
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
- 31 Aug 2018 Biomarkers information updated
- 16 Aug 2018 Planned End Date changed from 7 Mar 2020 to 28 Apr 2020.
- 16 Aug 2018 Planned primary completion date changed from 7 Mar 2020 to 28 Apr 2020.